2.88
0.18 (6.67%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Perspective Therapeutics, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -2.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.75 |
|
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 内部持股比例 | 18.83% |
| 机构持股比例 | 61.12% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tcg Crossover Management, Llc | 30 Jun 2026 | 7,915,567 |
| Commodore Capital Lp | 30 Jun 2026 | 6,336,782 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 4,214,582 |
| Spruce Street Capital Lp | 30 Jun 2026 | 3,693,931 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合